ProJect Pharmaceutics started business operations and opened its laboratory facilities in the Biotech-cluster in Martinsried, near Munich. ProJect Pharmaceutics (PJP) transforms proteins, peptides and delicate small molecules into pioneering drugs.
Adding value to client´s bio-therapeutic products is PJP´s mission, focused in an innovative concept of biopharmaceutical development called Advaceutics. Based on the Advaceutics concept, ProJect Pharmaceutics designs optimized pharmaceutical formulations and delivery systems that are stable, convenient and safe.
Tailored to these optimized systems the company develops cost-effective manufacturing processes and transfers those from its own pilot labs to large-scale manufacturing. ProJect Pharmaceutics makes sure that investigational products as well as new presentations of registered drugs are developed effectively and will run smoothly in clinical and commercial scale GMP manufacturing.
ProJect Pharmaceutics was founded and is managed by Andreas Schütz and Klaus Hellerbrand, two leading experts in protein formulation and pharmaceutical process development with many years of experience in bio-pharmaceutics. Their combined expertise and complementary set of qualifications enables ProJect Pharmaceutics to deliver the high-tech pharmaceutical services the team is known for and that are in increased demand for the global biopharmaceutical industry.
“In times of an increasingly globalizing and changing pharmaceutical value chain, capital efficiency in developing new drugs, paired with deep expertise and highly reliable quality of service are ever important for competitive pharmaceutical companies facing a challenging market environment”, says Dr. Andreas Schütz, Managing Director and Founder of ProJect Pharmaceutics. “We started our operations with an experienced team of biopharmaceutical professionals and already are working on several exciting projects“, comments Klaus Hellerbrand, Managing Director and Founder.
Transforming Proteins into Pioneering Drugs - ProJect Pharmaceutics Started Operations
News Dec 14, 2010
RELATED ARTICLES
The ramifications of bacteria's ability to become resistant to antibiotics can be seen in hospitals, public places, our food supply, and our water. Now, researchers have demonstrated how we could improve upon the ability of nature's exquisitely selective collection of antimicrobial enzymes to attack bacteria in a way that's much less likely to cause bacterial resistance.
READ MORE
The discovery in the 1990s that a mutation in a single gene of an experimental worm could double its lifespan set off a stampede of research on the molecular biology of aging and triggered hopes that drug therapies or other interventions could be developed to extend healthy human lifespan. But as is often the case in science, the genetic regulation of aging is more complicated than it first appeared.
READ MORELike what you just read? You can find similar content on the communities below.
Drug Discovery Proteomics & MetabolomicsTo personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free
LOGIN SUBSCRIBE FOR FREE
